SCHEMBL27712980

SCHEMBL27712980

CC(C)(NC(=O)c1cc(Cl)c2ccccc2c1Cc1ccc(C(F)(F)F)cn1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.53
▸ MRGPRX4 Q96LA9 1/20 0.43
▸ CXCR2 P25025 2/20 0.41
▸ GAA P10253 3/20 0.40
▸ POLB P06746 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ RPS6KA3 P51812 1/20 0.39
▸ P2RX7 Q99572 1/20 0.37
▸ MAPT P10636 2/20 0.37
▸ TRPM8 Q7Z2W7 1/20 0.37
▸ SORT1 Q99523 1/20 0.36
▸ HCRTR1 O43613 1/20 0.36
▸ HPGD P15428 3/20 0.36
▸ GLA P06280 1/20 0.36
▸ CNR1 P21554 2/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ PPARG P37231 1/20 0.35
▸ PPARD Q03181 1/20 0.35
▸ PPARA Q07869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27693276 0.90 KDM4E (0.41) KDM4EMRGPRX4CXCR2GAAPOLB
SCHEMBL485344 0.85 KDM4E (0.52) KDM4EMRGPRX4CXCR2GAAPOLB
SCHEMBL485692 0.77 MRGPRX4 (0.55) KDM4EMRGPRX4CXCR2
SCHEMBL485491 0.76 CXCR2 (0.44) KDM4EMRGPRX4CXCR2GAAPOLB
SCHEMBL485706 0.75 CXCR2 (0.44) KDM4EMRGPRX4CXCR2GAAPOLB
SCHEMBL10289725 0.75 KDM4E (0.50) KDM4ECXCR2P2RX7
SCHEMBL5179473 0.73 KDM4E (0.51) KDM4EMRGPRX4CXCR2GAAPOLB
SCHEMBL485303 0.72 KDM4E (0.52) KDM4EMRGPRX4CXCR2P2RX7TRPM8
SCHEMBL485816 0.72 KDM4E (0.52) KDM4EMRGPRX4CXCR2
SCHEMBL485152 0.72 KDM4E (0.53) KDM4EMRGPRX4CXCR2P2RX7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094830-A Fused bicyclic carboxamide derivatives for use as CXCR2 inhibitors in the treatment of inflammation SANOFI AVENTIS DEUTSCHLAND (DE) 2007-12-26 — — CN claimed
Send feedback